Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Dublin, August 9, 2021/PRNewswire/-"The global electrocardiograph market: focus on product types, end users, regions, COVID-19 impact, competitive landscape, and data from 22 countries/regions-2021-2031 analysis and The "Forecast" report has been added to ResearchAndMarkets.com's products.

By 2031, the global electrocardiograph market will reach 9.826.8 billion U.S. dollars.

Abbott Laboratories, Biotricity, Inc., BIOTRONIK SE & Co. KG, Boston Scientific Corporation, CardioComm Solutions, Inc., Cardioline SpA, Fukuda Denshi Co., Ltd., General Electric Company, Hill-Rom Holdings, Inc., iRhythm Technologies , Inc., Koninklijke Philips NV, Medtronic plc, Nihon Kohden Corporation, OSI Systems, Inc., Zoll Medical Corporation (Asahi Kasei Corporation)

Who should buy this report?

Key questions answered in the report

An electrocardiogram (ECG) machine records the electrical activity of your heart. The electrocardiograph detects the electrical signals that make the heart pump blood throughout the body. Conventional equipment and emerging equipment are two types of electrocardiographs based on product types. Conventional equipment can be divided into resting electrocardiograph and pressure electrocardiograph. The electrocardiograph is currently dominated by traditional equipment. In the past few decades, ECG monitoring systems have been created and widely used in the healthcare industry. With the emergence of intelligent support technologies, they have undergone tremendous changes. ECG monitoring equipment is now often used in hospitals, home care environments, outpatient clinic environments, and remote environments. In the part of traditional equipment, including resting electrocardiograph and pressure electrocardiograph, and in the part of emerging equipment, the report includes implantable circuit recorder, mobile heart telemetry, dynamic electrocardiogram monitor and cardiac event monitor.

The report on the global electrocardiograph market emphasizes that the market value in 2020 is 4.394.1 billion U.S. dollars and is expected to reach 9.826.8 billion U.S. dollars by the end of 2031. The market is expected to grow at a compound annual growth rate of 7.8% during the forecast period of 2021-2031.

In the global electrocardiograph market, progress has already taken place, and the industry is currently being conquered. With the emergence of advanced technologies that can be easily used in outpatient and home care environments, these new technologies under development have great potential to promote the overall growth of the market.

Accuracy, precision, timeliness and authenticity are the four foundations of good laboratory services. In order to improve the analysis difficulty of sample processing, clinical biochemists usually ignore the need for timeliness. On the other hand, clinicians often use timeliness as a benchmark for laboratory performance, expressed in turnaround time (TAT). Short-term TAT can help clinicians diagnose and treat patients as quickly as possible, and help patients to be discharged from the emergency department or inpatient services.

One of the most common problems in diagnosis is errors and incomplete diagnosis. False negative readings are the most typical problem of ECG. Any other symptoms of underlying heart disease must be considered, such as chest pain, and additional testing may be required. Delayed TAT and incomplete/erroneous diagnosis results will have a negative impact on the market.

Modern cardiac imaging may include multiple methods, which are essential to correctly characterize the anatomy and physiology of pediatrics and congenital heart disease. More and more newer imaging methods are used, such as cardiac magnetic resonance imaging (CMR) and cardiac computed tomography angiography (CCTA). When deciding on intervention or surgery for congenital or acquired heart disease, echocardiography and electrocardiogram (ECG) are still the gold standard for non-invasive diagnosis. Due to the rapid spread of medical imaging workstations, the company is working to improve the technology and make the software accessible to the public.

The company's growth of medical imaging workstations will be driven by the growing demand for digital platforms, as well as the advancement of new medical facilities and healthcare businesses. Due to these improvements in multimodal diagnostic imaging for cardiovascular diseases, the global electrocardiograph market is expected to increase.

The impact of COVID-19 on the global electrocardiograph market

Due to the increase in cardiac complications caused by the COVID-19 virus, the overall market for diagnostic electrocardiographs, especially traditional electrocardiographs, has had a positive impact at this stage; however, due to the high cost of equipment, compared with traditional heart monitors, implantable The influence of the loop recorder is small. Since most countries do not have the necessary infrastructure to handle large numbers of cases, the impact is even greater, especially in the first months of February and March.

The electrocardiograph (ECG) is one of the key instruments to measure the degree of heart involvement of COVID-19 patients and the impact of drugs in this situation because of its wide accessibility, low cost, and remote research capabilities.

5 Market dynamics 5.1 Impact analysis 5.2 Market drivers 5.2.1 Increased prevalence of cardiovascular disease (CVD) and other heart-related diseases 5.2.2 Increasing demand for instant diagnostic systems 5.2.3 End users’ demand for non-medical systems Increasing preference for invasive diagnostic technology over invasive technology 5.3 Market Limitation 5.3.1 Longer Turnaround Time (TAT) 5.3.2 Incomplete and Misdiagnosis 5.4 Market Trend 5.4.1 Demand for Holter Monitors Rising 5.4.2 Development of pluggable heart monitors 5.5.5.5 Market opportunity 1 Increasing market preference for multi-modal diagnostic imaging systems 5.5.2 Implementation of ECG in hybrid operating rooms

6 Global ECG Market 6.1 Global Market Outlook 6.2 Key Findings 6.3 Assumptions and Limitations

7 Global ECG market (by product type) 7.1 Overview 7.2 Market size and forecast 7.2.1 Traditional equipment 7.2.1.1 Resting ECG equipment 7.2.1.2 Stress ECG equipment 7.2.2 Emerging equipment 7.2.2.1 Implantable loop recorder 7.2 .2 Mobile Cardiac Telemetry.2 7.2.2.2.1.1 Lead-based mobile cardiac telemetry 7.2.2.2.2 Patch-based mobile cardiac telemetry 7.2.2.3 Holter monitor 7.2.2.4 Cardiac event monitor

8 Global ECG market (by end user) 8.1 Overview 8.1.1 Market size and forecast 8.1.1.1 Hospitals and clinics 8.1.1.2 Home care settings and outpatient surgery centers 8.1.1.3 Others

9 Global ECG Market (By Region)

10 Company Profile 10.1 Overview 10.2 Abbott Laboratories 10.2.1 Company Outlook 10.2.2 Company Description 10.2.3 Finance 10.2.4 SWOT Analysis 10.3 Biotricity, Inc. 10.3.1 Company Outlook 10.3.2 Company Description 10.3.3.4 SWOT.3 Finance Analysis 10.4 BIOTRONIK SE & Co. KG 10.4.1 Company Overview 10.4.2 Company Description 10.4.3 SWOT Analysis 10.5 Boston Scientific Corporation 10.5.1 Company Outlook 10.5.2 Company Description 10.5.3 Finance 10.5.4 SWOT Analysis 10.6 Aerobic Exercise Solution Inc. 10.6.1 Company Outlook 10.6.2 Company Description 10.6.3 Financial Status 10.6.4 SWOT Analysis 10.7 Cardioline SpA 10.7.1 Company Overview 10.7.2 Company Description 10.7.3 SWOT Analysis 10.8 Fukuda Denshi Co., Ltd. 10.8 Company Outlook 10.8.2 Company Description 10.8.3 Finance 10.8.4 SWOT Analysis 10.9 General Electric Company 10.9.1 Company Outlook 10.9.2 Company Description 10.9.3 Finance 10.9.4 SWOT Analysis 10.10 Hill-Rom Holdings, Inc. 10.10. 1 Company Outlook 10.10.2 Company y Description 10.10.3 Finance 10.10.4 SWOT Analysis 10.11 iRhythm Technologies, Inc. 10.11.1 Company Outlook 10.11.2 Company Description 10.11.3 Finance 10.11.4 SWOT Analysis 10.12 Koninklijke Company.12NV1 Company Outlook 10.12.3 Financial 10.12.4 SWOT analysis 10.13 Medtronic plc 10.13.1 Company outlook 10.13.2 Company description 10.13.3 Financial 10.13.4 SWOT analysis 10.14 Nihon Kohden Corporation 10.14.1 Company outlook 14.3.14.3 Company outlook 14.3.4 SWOT Analysis 10.15 OSI Systems, Inc. 10.15.1 Company Outlook 10.15.2 Company Description 10.15.3 Finance 10.15.4 SWOT Analysis 10.16 Zoll Medical Corporation (Asahi Kasei Corporation) 10. 16.1 Company Outlook 10.110.16 Company Description 3 Finance 10.16.4 SWOT Analysis

For more information about this report, please visit https://www.researchandmarkets.com/r/d2ktjg

Media Contact: Laura Wood, Senior Manager, Research and Marketing Department [email protection]       

Call +1-917-300-0470 during EST office hours toll-free number in the US/Canada at +1-800-526-8630 GMT during office hours call +353-1-416-8900

US Fax: 646-607-1904 Fax (Outside the US): +353-1-481-1716

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time